1. Phase II Study of Bendamustine in Relapsed Chemotherapy Sensitive or Resistant Small-Cell Lung Cancer 
Philip E. Lammers, MD, Yu Shyr, PhD, Chung-I Li, PhD, Anne Smith Hutchison, MD, Alan Sandler, MD, David Paul Carbone, MD, PhD, David H. Johnson, MD, Vicki Leigh Keedy, MD, Leora Horn, MD, Msc 
Journal of Thoracic Oncology 
Volume 9, Issue 4, Pages (April 2014)
DOI: /JTO
Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

2. FIGURE 1
A, TTP; Kaplan–Meier curve showing TTP with 95% CI of 50 patients treated with bendamustine for relapsed SCLC. The median TTP in this population was 4.0 months (95% CI, 3.3–5.4 months). B, TTP in chemosensitive and chemoresistant disease. Kaplan–Meier curves showing TTP with 95% CI of 29 patients treated with bendamustine for relapsed SCLC with chemosensitive disease and TTP with 95% CI of 21 patients treated with bendamustine for relapsed SCLC with chemoresistant disease. The median TTP in patients with chemosensitive disease was 4.2 months (95% CI, 3.3–6.0 months) and those with chemoresistant disease had a median TTP of 3.4 months (95% CI, 2.7–∞ months). There was no difference in median TTP between the two groups (p = 0.41). TTP, time to progression; CI, confidence interval; SCLC, small-cell lung cancer.
Journal of Thoracic Oncology 2014 9, DOI: ( /JTO )
Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

3. FIGURE 2
A, OS; Kaplan–Meier curve showing OS with 95% CI of 50 patients treated with bendamustine for relapsed SCLC. The median OS in this population was 4.8 months (95% CI, 3.8–6.3 months). B, OS in chemosensitive and chemoresistant disease. Kaplan–Meier curves showing OS with 95% CI of 29 patients treated with bendamustine for relapsed SCLC with chemosensitive disease and OS with 95% CI of 21 patients treated with bendamustine for relapsed SCLC with chemoresistant disease. Patients with chemosensitive disease had a median OS of 5.7 months (95% CI, 4.1–7.4 months) and patients with chemoresistant disease had a median OS of 4.1 months (95% CI, 2.5–7.9 months). There was no difference in median OS between the two groups (p = 0.53). OS, overall survival; CI, confidence interval; SCLC, small-cell lung cancer.
Journal of Thoracic Oncology 2014 9, DOI: ( /JTO )
Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions